PFGIA
CRSP icon

Patriot Financial Group Insurance Agency’s CRISPR Therapeutics CRSP Stock Holding History

Patriot Financial Group Insurance Agency’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
23,648
-23,902
-50% -$1.26M 0.13% 183
2026
Q1 		$2.26M Buy
47,550
+24,316
+105% +$1.28M 0.13% 196
2025
Q4 		$1.22M Sell
23,234
-52
-0.2% -$3.11K 0.14% 179
2025
Q3 		$1.51M Buy
23,286
+91
+0.4% +$5.22K 0.19% 139
2025
Q2 		$1.13M Buy
23,195
+450
+2% +$17.4K 0.13% 190
2025
Q1 		$774K Buy
22,745
+87
+0.4% +$3.69K 0.1% 223
2024
Q4 		$892K Sell
22,658
-6,928
-23% -$327K 0.12% 200
2024
Q3 		$1.39M Buy
29,586
+2,165
+8% +$110K 0.19% 130
2024
Q2 		$1.48M Buy
27,421
+80
+0.3% +$4.63K 0.22% 106
2024
Q1 		$1.86M Sell
27,341
-1,738
-6% -$124K 0.3% 75
2023
Q4 		$1.82M Buy
29,079
+2,082
+8% +$115K 0.34% 61
2023
Q3 		$1.23M Buy
26,997
+462
+2% +$23.9K 0.25% 98
2023
Q2 		$1.49M Buy
26,535
+851
+3% +$48.3K 0.28% 81
2023
Q1 		$1.16M Buy
25,684
+12,226
+91% +$594K 0.24% 102
2022
Q4 		$547K Buy
13,458
+702
+6% +$37.2K 0.07% 194
2022
Q3 		$834K Buy
12,756
+8,350
+190% +$605K 0.2% 126
2022
Q2 		$268K Buy
4,406
+2,157
+96% +$127K 0.05% 324
2022
Q1 		$141K Buy
2,249
+1,011
+82% +$63.5K 0.03% 484
2021
Q4 		$94K Buy
1,238
+178
+17% +$15.6K 0.02% 669
2021
Q3 		$119K Hold
1,060
– – 0.02% 591
2021
Q2 		$172K Sell
1,060
-30
-3% -$3.65K 0.03% 464
2021
Q1 		$133K Buy
1,090
+231
+27% +$34.9K 0.03% 483
2020
Q4 		$132K Sell
859
-380
-31% -$44.9K 0.03% 426
2020
Q3 		$104K Sell
1,239
-15,253
-92% -$1.35M 0.03% 380
2020
Q2 		$1.21M Sell
16,492
-3,613
-18% -$211K 0.46% 43
2020
Q1 		$853K Buy
20,105
+945
+5% +$48.8K 0.39% 51
2019
Q4 		$1.17M Sell
19,160
-1,620
-8% -$88.5K 0.44% 41
2019
Q3 		$852K Sell
20,780
-3,864
-16% -$185K 0.38% 50
2019
Q2 		$1.16M Buy
24,644
+1,558
+7% +$62.3K 0.5% 35
2019
Q1 		$825K Sell
23,086
-4,986
-18% -$172K 0.42% 40
2018
Q4 		$802K Buy
28,072
+27,247
+3,303% +$947K 0.53% 32
2018
Q3 		$37K Buy
+825
New +$43.2K 0.02% 356
2018
Q2 		– Sell
-34,107
Closed -$1.48M – 653
2018
Q1 		$1.48M Buy
34,107
+29,217
+597% +$1.21M 1.09% 15
2017
Q4 		$127K Buy
+4,890
New +$92.9K 0.1% 175

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Patriot Financial Group Insurance Agency's CRSP Position: Q2 2026 in Review

Patriot Financial Group Insurance Agency reduced its CRISPR Therapeutics (CRSP) stake by 50% in Q2 2026, selling an estimated $1.26M and leaving 23,648 shares worth $1.29M. The position accounts for 0.13% of the portfolio, ranked #183.

Patriot Financial Group Insurance Agency first reported a position in CRSP in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.26M in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Patriot Financial Group Insurance Agency held 23,648 shares of CRISPR Therapeutics worth $1.29M as of Q2 2026.
  • Patriot Financial Group Insurance Agency sold 23,902 CRISPR Therapeutics shares in Q2 2026, an estimated $1.26M.
  • CRISPR Therapeutics made up 0.13% of Patriot Financial Group Insurance Agency's portfolio in Q2 2026, its #183 holding.
  • Patriot Financial Group Insurance Agency first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • Patriot Financial Group Insurance Agency's CRISPR Therapeutics position peaked at $2.26M in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Patriot Financial Group Insurance Agency's 13F filing for Q2 2026, filed 16 Jul 2026.